From conventional to cutting edge: The new era of biologics in treatment of psoriasis

Dermatologic Therapy

Volumn 21, Issue 2, 2008, Pages 131-141

  Tzu, Julia ^a   Kerdel, Francisco ^a,b  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF MIAMI HOSPITAL   (United States)

Author keywords

Biologics; Psoriasis; TNF

Indexed keywords

ABT 874; ADALIMUMAB; ALEFACEPT; CNTO 1275; CYCLOSPORIN; EFALIZUMAB; ETANERCEPT; ETRETIN; HU 1124; HYDROXYUREA; INFLIXIMAB; LEFLUNOMIDE; METHOTREXATE; METHOXSALEN; PLACEBO; SALAZOSULFAPYRIDINE; TIOGUANINE; UNCLASSIFIED DRUG;

ANKYLOSING SPONDYLITIS; ASPERGILLOSIS; CARDIOVASCULAR DISEASE; CHILL; CLINICAL TRIAL; COLON ADENOCARCINOMA; CONGESTIVE HEART FAILURE; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; COUGHING; CROHN DISEASE; CRYPTOCOCCOSIS; DEMYELINATING DISEASE; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG EFFICACY; DRUG INHIBITION; DRUG MECHANISM; DRUG SAFETY; DRUG WITHDRAWAL; DYSPEPSIA; FATIGUE; FEVER; FOOD AND DRUG ADMINISTRATION; HEADACHE; HEALTH HAZARD; HEPATITIS; HISTOPLASMOSIS; HUMAN; HYPERSENSITIVITY; HYPERTENSION; INFECTION; INFLUENZA; INJECTION SITE REACTION; LEUKEMIA; LEUKOPENIA; LISTERIOSIS; LIVER FAILURE; LOADING DRUG DOSE; LUPUS LIKE SYNDROME; LYMPHOCYTOPENIA; LYMPHOMA; MONOTHERAPY; MYALGIA; MYCOSIS; NAUSEA; NEPHROTOXICITY; PANCYTOPENIA; PAPULAR RASH; PATHOGENESIS; PHOTOTHERAPY; PRURITUS; PSORIASIS; PSORIATIC ARTHRITIS; PUVA; RANDOMIZED CONTROLLED TRIAL; REVIEW; RHEUMATOID ARTHRITIS; RHINOPHARYNGITIS; SIDE EFFECT; SINUSITIS; SKIN CANCER; SQUAMOUS CELL CARCINOMA; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT RESPONSE; TUBERCULOSIS; ULTRAVIOLET B RADIATION; UNSPECIFIED SIDE EFFECT; UPPER RESPIRATORY TRACT INFECTION;

ANTI-INFLAMMATORY AGENTS; BIOLOGICAL PRODUCTS; DERMATOLOGIC AGENTS; DERMATOLOGY; HUMANS; PATIENT SELECTION; PSORIASIS; TREATMENT OUTCOME;

EID: 41849130250     PISSN: 13960296     EISSN: 15298019     Source Type: Journal    
DOI: 10.1111/j.1529-8019.2008.00180.x     Document Type: Review

References (62)

1. van de Kerkhof PC. Consistent control of psoriasis by continuous long-term therapy: the promise of biological treatments. J Eur Acad Dermatol Venereol 2006 : 20 : 639 650.
2. Smith CH, Anstey AV, Barker JN, et al. British Association of Dermatologists guidelines for use of biological interventions in psoriasis 2005. Br J Dermatol 2005 : 153 : 486 497.
3. Sauder DN, Mamelak AJ. Understanding the new clinical landscape for psoriasis: a comparative review of biologics. J Cutan Med Surg 2004 : 8 : 205 212.
4. Pittelkow MR, Perry HO, Muller SA, Maughan WZ, O'Brien PC. Skin cancer in patients with psoriasis treated with coal tar. A 25-year follow-up study. Arch Dermatol 1981 : 117 : 465 468.
5. Menter A, Griffiths CE. Current and future management of psoriasis. Lancet 2007 : 370 : 272 284.
6. Nijsten TE, Stern RS. The increased risk of skin cancer is persistent after discontinuation of psoralen+ultraviolet A: a cohort study. J Invest Dermatol 2003 : 121 : 252 258.
7. Stern RS, Bagheri S, Nichols K. The persistent risk of genital tumors among men treated with psoralen plus ultraviolet A (PUVA) for psoriasis. J Am Acad Dermatol 2002 : 47 : 33 39.
8. Strober BE, Siu K, Menon K. Conventional systemic agents for psoriasis. A systematic review. J Rheumatol 2006 : 33 : 1442 1446.
9. Tzu J, Mamelak AJ, Sauder DN. Current advancements in the treatment of psoriasis: immunobiologic agents. Clinical and Applied Immunology Reviews 2006 : 6 : 99 130.
10. Mascelli MA, Zhou H, Sweet R, et al. Molecular, biologic, and pharmacokinetic properties of monoclonal antibodies: impact of these parameters on early clinical development. J Clin Pharmacol 2007 : 47 : 553 565.
11. Gottlieb AB, Krueger JG, Wittkowski K, et al. Psoriasis as a model for T-cell-mediated disease: immunobiologic and clinical effects of treatment with multiple doses of efalizumab, an anti-CD11a antibody. Arch Dermatol 2002 : 138 : 591 600.
12. Shear NH, Langley RG, Ho V. Efalizumab, a reversible T-cell modulator for psoriasis. J Cutan Med Surg 2006 : 9 (Suppl. 1 4 9.
13. Boehncke WH, Prinz J, Gottlieb AB. Biologic therapies for psoriasis. A systematic review. J Rheumatol 2006 : 33 : 1447 1451.
14. Fretzin S, Crowley J, Jones L, Young M, Sobell J. Successful treatment of hand and foot psoriasis with efalizumab therapy. J Drugs Dermatol 2006 : 5 : 838 846.
15. Papp KA, Caro I, Leung HM, Garovoy M, Mease PJ. Efalizumab for the treatment of psoriatic arthritis. J Cutan Med Surg 2007 : 11 : 57 66.
16. Nast A, Kopp I, Augustin M, et al. German evidence-based guidelines for the treatment of Psoriasis vulgaris (short version). Arch Dermatol Res 2007 : 299 : 111 138.
17. Vugmeyster Y, Kikuchi T, Lowes MA, et al. Efalizumab (anti-CD11a)-induced increase in peripheral blood leukocytes in psoriasis patients is preferentially mediated by altered trafficking of memory CD8+ T cells into lesional skin. Clin Immunol 2004 : 113 : 38 46.
18. Gordon KB, Papp KA, Hamilton TK, et al. Efalizumab for patients with moderate to severe plaque psoriasis: a randomized controlled trial. Jama 2003 : 290 : 3073 3080.
19. Menter A, Gordon K, Carey W, et al. Efficacy and safety observed during 24 weeks of efalizumab therapy in patients with moderate to severe plaque psoriasis. Arch Dermatol 2005 : 141 : 31 38.
20. Gottlieb AB, Hamilton T, Caro I, et al. Long-term continuous efalizumab therapy in patients with moderate to severe chronic plaque psoriasis: updated results from an ongoing trial. J Am Acad Dermatol 2006 : 54 : S154 S163.
21. Pirzada S, Tomi Z, Gulliver W. A review of biologic treatments for psoriasis with emphasis on infliximab. Skin Therapy Lett 2007 : 12 : 1 4.
22. Langley RG, Carey WP, Rafal ES, et al. Incidence of infection during efalizumab therapy for psoriasis: analysis of the clinical trial experience. Clin Ther 2005 : 27 : 1317 1328.
23. Papp KA, Ho V, Langley R, et al. Strategies for optimizing treatment with efalizumab in moderate to severe psoriasis. J Cutan Med Surg 2006 : 9 (Suppl. 1 26 32.
24. Leonardi CL, Toth D, Cather JC, et al. A review of malignancies observed during efalizumab (Raptiva) clinical trials for plaque psoriasis. Dermatology 2006 : 213 : 204 214.
25. White JM, Smith CH, Robson A, Ash G, Barker JN. DRESS syndrome caused by efalizumab. Clin Exp Dermatol 2007 : 33 : 50 52.
26. da Silva AJ, Brickelmaier M, Majeau GR, et al. Alefacept, an immunomodulatory recombinant LFA-3/IgG1 fusion protein, induces CD16 signaling and CD2/CD16-dependent apoptosis of CD2(+) cells. J Immunol 2002 : 168 : 4462 4471.
27. Gottlieb AB, Casale TB, Frankel E, et al. CD4+ T-cell-directed antibody responses are maintained in patients with psoriasis receiving alefacept: results of a randomized study. J Am Acad Dermatol 2003 : 49 : 816 825.
28. Hodak E, David M. Alefacept: a review of the literature and practical guidelines for management. Dermatol Ther 2004 : 17 : 383 392.
29. Biogen (http://www.amevive.com/pdf/AMEVIVEPI.pdf), pp package insert.
30. Lebwohl M, Christophers E, Langley R, et al. An international, randomized, double-blind, placebo-controlled phase 3 trial of intramuscular alefacept in patients with chronic plaque psoriasis. Arch Dermatol 2003 : 139 : 719 727.
31. Goffe B, Papp K, Gratton D, et al. An integrated analysis of thirteen trials summarizing the long-term safety of alefacept in psoriasis patients who have received up to nine courses of therapy. Clin Ther 2005 : 27 : 1912 1921.
32. Graves JE, Nunley K, Heffernan MP. Off-label uses of biologics in dermatology: rituximab, omalizumab, infliximab, etanercept, adalimumab, efalizumab, and alefacept (part 2 of 2). J Am Acad Dermatol 2007 : 56 : e55 e79.
33. Partsch G, Steiner G, Leeb BF, et al. Highly increased levels of tumor necrosis factor-alpha and other proinflammatory cytokines in psoriatic arthritis synovial fluid. J Rheumatol 1997 : 24 : 518 523.
34. Ettehadi P, Greaves MW, Wallach D, Aderka D, Camp RD. Elevated tumour necrosis factor-alpha (TNF-alpha) biological activity in psoriatic skin lesions. Clin Exp Immunol 1994 : 96 : 146 151.
35. Brounell I. Sexy and 17: TH17 effector T cells and psoriasis. J Drugs Dermatol 2007 : 6 : 853 856.
36. Bongartz T, Sutton AJ, Sweeting MJ, et al. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. Jama 2006 : 295 : 2275 2285.
37. Bissonnette R. Etanercept for the treatment of psoriasis. Skin Therapy Lett 2006 : 11 : 1 4.
38. Goiriz R, Dauden E, Perez-Gala S, Guhl G, Garcia-Diez A. Flare and change of psoriasis morphology during the course of treatment with tumour necrosis factor blockers. Clin Exp Dermatol 2007 : 32 : 176 179.
39. Furst DE, Wallis R, Broder M, Beenhouwer DO. Tumor necrosis factor antagonists: different kinetics and/or mechanisms of action may explain differences in the risk for developing granulomatous infection. Semin Arthritis Rheum 2006 : 36 : 159 167.
40. Tyring S, Gottlieb A, Papp K, et al. Etanercept and clinical outcomes, fatigue, and depression in psoriasis: double-blind placebo-controlled randomised phase III trial. Lancet 2006 : 367 : 29 35.
41. Calabrese LH, Zein N. Biologic agents and liver toxicity: an added concern or therapeutic opportunity? Nat Clin Pract Rheumatol 2007 : 3 : 422 423.
42. Tyring S, Gordon KB, Poulin Y, et al. Long-term safety and efficacy of 50 mg of etanercept twice weekly in patients with psoriasis. Arch Dermatol 2007 : 143 : 719 726.
43. Moore A, Gordon KB, Kang S, et al. A randomized, open-label trial of continuous versus interrupted etanercept therapy in the treatment of psoriasis. J Am Acad Dermatol 2007 : 56 : 598 603.
44. Sanchez Carazo JL, Mahiques Santos L, Oliver Martinez V. Safety of etanercept in psoriasis: a critical review. Drug Saf 2006 : 29 : 675 685.
45. Amgen (http://www.enbrel.com/pdf/enbrel_pi.pdf), pp package insert.
46. Scallon B, Cai A, Solowski N, et al. Binding and functional comparisons of two types of tumor necrosis factor antagonists. J Pharmacol Exp Ther 2002 : 301 : 418 426.
47. Centocor (http://www.remicade.com/remicade/assets/HCP_PPI.pdf), pp package insert.
48. Reich K, Nestle FO, Papp K, et al. Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial. Lancet 2005 : 366 : 1367 1374.
49. Menter A, Feldman SR, Weinstein GD, et al. A randomized comparison of continuous vs. intermittent infliximab maintenance regimens over 1 year in the treatment of moderate-to-severe plaque psoriasis. J Am Acad Dermatol 2007 : 56 : e31 e15.
50. Baert F, Noman M, Vermeire S, et al. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. N Engl J Med 2003 : 348 : 601 608.
51. Ting PT, Koo JY. Use of etanercept in human immunodeficiency virus (HIV) and acquired immunodeficiency syndrome (AIDS) patients. Int J Dermatol 2006 : 45 : 689 692.
52. Hamilton CD. Infectious complications of treatment with biologic agents. Curr Opin Rheumatol 2004 : 16 : 393 398.
53. Thomas VD, Yang FC, Kvedar JC. Biologics in psoriasis: a quick reference guide. J Am Acad Dermatol 2005 : 53 : 346 351.
54. Abbott (http://www.rxabbott.com/pdf/humira.pdf), pp package insert.
55. Scheinfeld N. Adalimumab: a review of side effects. Expert Opin Drug Saf 2005 : 4 : 637 641.
56. Gordon KB, Langley RG, Leonardi C, et al. Clinical response to adalimumab treatment in patients with moderate to severe psoriasis: double-blind, randomized controlled trial and open-label extension study. J Am Acad Dermatol 2006 : 55 : 598 606.
57. Menter A, Tyring SK, Gordon K, et al. Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trial. J Am Acad Dermatol 2007 : 58 : 106 115.
58. Saurat JH, Stingl G, Dubertret L, et al. Efficacy and safety results from the randomized controlled comparative study of adalimumab vs. methotrexate vs. placebo in patients with psoriasis (CHAMPION). Br J Dermatol 2007 : 158 : 558 566.
59. Leonardi CL et al 2007) Ustekinumab (CNTO-1275). Paper presented at World Congress of Dermatology. Buenos Aires, Argentina.
60. Gordon KB et al. (2007) ABT-874 in Psoriasis: Phase II Study Results. Paper presented at World Congress of Dermatology. Buenos Aires, Argentina.
61. Leonardi CL, Papp KA, Gordon KB, et al. Extended efalizumab therapy improves chronic plaque psoriasis: results from a randomized phase III trial. J Am Acad Dermatol 2005 : 52 : 425 433.
62. Krueger GG, Papp KA, Stough DB, Loven KH, Gulliver WP, Ellis CN, et al. A randomized, double-blind, placebo-controlled phase III study evaluating efficacy and tolerability of 2 courses of alefacept in patients with chronic plaque psoriasis. J Am Acad Dermatol 2002 : 47 : 821 833.